Related Experiment Video
Updated: Sep 21, 2025
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
2.9K
[Apomorphine and frontal dysfunction in Parkinson's disease]
G Fernández-Pajarín1, I Martín-Jiménez2, B Ares-Pensado2
1Hospital Clínico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, España.
Revista De Neurologia
|May 31, 2022
Summary
Continuous subcutaneous apomorphine infusion may improve executive dysfunction and apathy in Parkinson's disease patients. This treatment targets frontal dysfunction by enhancing dopaminergic activity, offering potential benefits for cognitive and affective symptoms.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Parkinson's disease (PD) frequently presents with dysexecutive disorder and apathy, indicative of frontal lobe dysfunction.
- The precise impact of continuous subcutaneous apomorphine infusion on these specific frontal symptoms in PD remains incompletely understood.
Purpose of the Study:
- To investigate the effects of continuous subcutaneous apomorphine infusion on dysexecutive symptoms and apathy in Parkinson's disease.
- To explore the potential of apomorphine's pharmacological profile in mitigating frontal dysfunction associated with PD.
Main Methods:
- A comprehensive literature search was conducted to identify relevant studies on apomorphine and Parkinson's disease.
- Analysis of selected studies focused on the outcomes related to executive functions and apathy.
Main Results:
- Apomorphine infusion demonstrated improvements in cognitive tasks assessing planning and verbal fluency.
- The treatment also showed positive effects on attention and reduced apathy in patients.
Conclusions:
- Apomorphine's unique pharmacological action, particularly its enhanced activity on D1-type dopaminergic receptors, suggests a beneficial role.
- This may translate to improved frontal dysfunction in Parkinson's disease, addressing key cognitive and affective symptoms.
Related Concept Videos
01:24Parkinson's Disease: Treatment
396
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
396
01:15Parkinson's Disease: Overview
732
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
732
01:29Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
01:31Direct-Acting Cholinergic Agonists: Pharmacokinetics
1.4K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.4K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
938
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
938
01:22Alzheimer's Disease: Treatment
270
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
270